BioVie 10-K: $22.1M Loss, Going Concern, and Massive Dilution Headroom
BIVI has more than doubled off its 52-week low of $0.82 on elevated volume (52× avg).
Summary
BioVie's 10-K shows a $22.1M loss, $9M cash, going concern warning, and 792M shares of dilution headroom. Class action certified.
Key Events · Earnings and Guidance · BIVI
-
Going Concern Warning
Auditors and management state substantial doubt about BioVie's ability to continue as a going concern, with only $9.0 million in cash and a $22.1 million net loss for fiscal 2026.
-
Massive Dilution Headroom
Authorized shares of 800 million versus 7.5 million outstanding leaves 792.5 million shares available for issuance, enough to dilute existing holders by over 100x if fully used.
-
Active Financing Overhang
The 10-K confirms the $300 million S-3 shelf and the upsized $75 million best-efforts offering at $1.33 per share, both of which would add significant dilution at current prices.
-
Securities Class Action Certified
The court granted class certification on June 18, 2026, in the securities litigation related to the Phase 3 Alzheimer's trial, with a $2 million insurance deductible.
Analysis · BIVI · Life Sciences
The annual report confirms a $22.1 million net loss and only $9.0 million in cash, with management reiterating substantial doubt about its ability to continue as a going concern. With 800 million authorized shares against 7.5 million outstanding, there is room for extreme dilution if the company taps the $300 million shelf or the $75 million best-efforts offering already in progress. The filing also discloses that a securities class action was certified on June 18, 2026, adding legal overhang to a cash-strapped biotech.
How filings like this one have moved
In the 30 days to Nov 5, 2026, 43.4% of the 1274 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIVI was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.8M. The 52-week trading range was $0.82 to $3.79. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.